Biophysical Analysis in Antibody Development
Antibodies have high specificity and affinity and can achieve high efficiency, low-side effects, targeted treatment, and prevention effects, so they have become the research focus in the pharmaceutical field. With the gradual maturity and promotion of biophysical technology, it plays a key role in the antibody development process. The discovery and optimization of antibodies can be further accelerated by accurately measuring and analyzing the interaction between antibodies and antigens.
CD BioSciences has advanced biophysical technologies such as X-ray crystallography, differential scanning calorimetry (DSC), biolayer interferometry (BLI), dynamic light scattering (DLS), thermal shift assay (TSA), etc., which can monitor the binding kinetics and thermodynamic properties between molecules in real-time. These technologies not only improve the efficiency of antibody screening but also provide in-depth insights into binding mechanisms to help optimize the affinity and specificity of antibodies. By applying these technologies, we provide customers with high-precision and high-efficiency antibody development solutions, ensuring that every stage of antibodies from discovery to final production meets the highest standards.
Figure 1. X-ray crystal structures of D59C MelBSt with bound α-NPG or DDMB. (Guan L, et al., 2021)
Our Professional Services
CD BioSciences has a top biophysical analysis platform to provide customers with comprehensive and professional antibody development services.
Our team uses advanced biolayer interferometry (BLI) technology to help customers understand the interaction between antibodies and antigens. We help accelerate the development of antibody drugs through efficient and accurate antibody-antigen interaction analysis.
We provide thermal stability evaluation services for antibodies to help customers deeply understand the structural stability of antibodies under temperature changes and its influencing factors, further opening up new avenues for antibody development.
Our platform supports the characterization of antibody structure and uses biophysical techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and surface plasmon resonance (SPR) to reveal the three-dimensional structure of antibodies and help customers understand their stability and function.
We combine knowledge and technology in the field of physics to help customers conduct a comprehensive analysis of antibody particle size distribution and aggregation state through biophysical techniques such as dynamic light scattering (DLS) and multi-angle light scattering (MALS).
Our Technology Platform
- Differential Scanning Calorimetry (DSC)
- Mass Spectrometry (MS)
- Multi-dimensional Nuclear Magnetic Resonance (NMR)
- Dynamic Light Scattering (DLS)
- isothermal Titration Calorimetry (lTC)
- X-ray Crystallography
- Multiangle Laser Light Scattering Detector (MALLS)
- Surface Plasmon Resonance (SPR)
- Biolayer Interferometry (BLl)
Our Advantages
- Professional and reliable. We have the most advanced technology platform and equipment to ensure that we provide customers with accurate and reliable data.
- Strong technical support. Our scientific research team is composed of experienced biophysicists who are familiar with all aspects of antibody development and the latest technologies and can provide guidance to customers.
- One-stop service process. We provide one-stop service from customized solutions to delivery results, saving customers time.
- Customization. We will design solutions according to the different needs of customers to ensure the smooth progress of the project.
CD BioSciences is committed to providing customers with world-class antibody development services. Through our biophysical technology platform, we help customers accelerate the antibody development process and improve the quality and performance of antibodies. If you have any needs or questions, please feel free to contact us and our expert team will serve you wholeheartedly.
Reference
- Guan L, Hariharan P. (2021). X-ray crystallography reveals a molecular recognition mechanism for sugar binding in a melibiose transporter MelB[J]. Communications Biology. 4(1): 931.
For research use only, not
intended for any clinical use.
Related Services
